Drugs / Lactobacillus rhamnosus GG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06310733 | Mar 2024 → Dec 2025 | functional colonic disease | Prince of Songkla University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus rhamnosus GG | “Hence, several studies, specifically in western countries, reported the role of probiotics, specifically Lactobacillus rhamnosus GG (LGG), in modulating abdominal symptoms in...” NCT06310733 ↗ |
| Known as | LGG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06310733 ↗ |
| Route | Oral | “Participants will take 10 mL of a suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution” NCT06310733 ↗ |